According to the website of the U.S. District Court for the Northern District of Illinois, the multidistrict testosterone therapy litigation MDL 2545 now includes 1,530 testosterone lawsuits—nearly 200 more than it did just one month ago. The multidistrict testosterone litigation was established in June 2014, and initially consisted of eight separate testosterone lawsuits. Testosterone lawsuits claim that testosterone therapy products from companies like AbbVie and Eli Lilly ...
Testosterone MDL Cases Now Total over 1,500
Posted May 9, 2015 in Product News and Recalls | Testosterone Therapy
Study Finds Common Chemical Exposure May Cause Low Testosterone Levels
Posted October 8, 2014 in Product News and Recalls | Testosterone Therapy
Phthalates, common chemicals found in many plastics and consumer products may have a negative effect on testosterone levels in men, women, and children. An article in MedlinePlus reports of a University of Michigan study which examined the effects of exposure to phthalates on testosterone levels.
The study, published in the Journal of Clinical Endocrinology & Metabolism, found that higher level exposure to the chemicals was associated with an 11 to 24 percent ...
continue reading...Testosterone Therapy Linked to Decreased Cognition in Caucasian Men
Posted September 29, 2014 in Product News and Recalls | Testosterone Therapy
Scientists at the University of North Texas Health Science Center have released a study citing links between testosterone therapy and cognitive issues in Caucasian men. The study focused on the effect of testosterone-replacement therapy on men suffering from oxidative stress, a condition correlated with blood clots. According to the article, oxidative stress can in turn cause testosterone therapy to have additional side-effects.
The study indicates that in Caucasian males ...
continue reading...FDA Adds New Warning for Testosterone Therapy Products
Posted September 17, 2014 in Product News and Recalls | Testosterone Therapy
The Food and Drug Administration (FDA) recently issued a new safety alert stating that men who use testosterone therapy products are at an increased risk for venous blood clots, a condition referred to as venous thromboembolism (VTE). The FDA is requiring all manufacturers of testosterone therapy products to include on labels a general warning about the heightened VTE risks.
Venous blood clots are as they sound — blood clots that occur in the veins. ...
continue reading...Has There Been a Testosterone Replacement Therapy Recall?
Posted August 4, 2014 in Product News and Recalls | Testosterone Therapy
Products designed to treat low testosterone levels in men, also referred to as “low-T,” have been linked to serious side-effects that can be extremely dangerous. While the Federal Food and Drug Administration (FDA) has not issued a recall, it did issue a safety communication in January of 2014 advising the public that the agency was investigating whether testosterone replacement therapy drugs increased patients’ risk of adverse cardiac events, including heart attack and stroke.
Many Different Forms ...
continue reading...FDA Says Testosterone Products Should Warn About Risk of Venous Blood Clots
Posted July 21, 2014 in Product News and Recalls | Testosterone Therapy
The U.S. Food and Drug Administration issued a statement that all testosterone therapy products on the market must include a warning label about the general risk of blood clotting in the veins.
Testosterone therapy drugs have been marketed heavily to men with the condition coined Low-T. Men with fatigue or diminished sex drive supposedly do not have enough testosterone, and can reduce these symptoms by taking testosterone replacement drugs. By contrast, some doctors believe that testosterone ...
continue reading...
